|
| Identification |
| Molecular Structure |
 |
CAS No. |
155213-67-5 |
| Molecular Formula |
C37H48N6O5S2 |
| Molecular Weight |
720.95 |
| Name |
Ritonavir |
| Synonymous |
1,3-Thiazol-5-ylmethyl N-[(2S,3S,5R)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenyl-hexan-2-yl]carbamate |
| Properties |
| Melting Point |
N/A
|
| Safety & Transportation Information |
| Harzard Symbols |
|
| Hs code |
|
| Supplier Specification |
| Appearance |
|
| Purity |
|
| Packages |
1kg/tin
|
| Productivity |
|
| Storage |
|
| Notes |
Mechanism of Action: Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Ritonavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. Ritonavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Indication and Usage: Indicated in combination with other antiretroviral agents for the treatment of HIV-infection
|
|
|
|